perenostobart (SRF617)

P2, N=16, Terminated, Coherus Biosciences, Inc. | Completed --> Terminated; The study was terminated for strategic reasons, not due to any safety concerns.

P1, N=85, Completed, Surface Oncology | Active, not recruiting --> Completed | N=177 --> 85

P1, N=177, Active, not recruiting, Surface Oncology | Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Aug 2023

P2, N=40, Active, not recruiting, Surface Oncology | Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> May 2023

P1, N=177, Recruiting, Surface Oncology | N=100 --> 177

Methods Pts with advanced solid tumors were enrolled in a phase 1 dose-escalation study of SRF617 (NCT04336098) to establish preliminary safety as monotherapy as well as in combination with gemcitabine + nab-paclitaxel (GA) or pembrolizumab (P) and to identify doses suitable for monotherapy and combination expansion cohorts...Legal entity responsible for the study Surface Oncology, Cambridge, MA, USA. Funding Surface Oncology, Cambridge, MA, USA.

Wild-type mice bearing subcutaneous (s.c.) KPC1245 tumors were treated with anti-murine CD39 antibody, alone or in combination with gemcitabine. These studies demonstrate the therapeutic potential of targeting CD39 for the treatment of cancer. SRF617 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors (NCT04336098) and in combination with chemotherapy in patients with pancreatic cancer.

Inhibition of CD39 potentiates the activity of chemotherapy and immunotherapy agents to improve tumor growth inhibition and survival in mice. These findings support future clinical studies of SRF617 as monotherapy and in combination with other therapeutic agents in treating patients with cancer.